RxSight (RXST) Stock Analysis & AI Equity Report

Medical - Devices USD Explore free reports

RxSight (RXST) overview

RxSight (RXST) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 134m and operating profit of USD -48.2m; the year-end share price was 10.42 USD and market capitalisation was USD 430m. RxSight is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get RxSight's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 276mFY 2025
Share price10.42 USDFY 2025 year end
RevenueUSD 134mFY 2025
Operating profitUSD -48.2mFY 2025
Net earningsUSD -38.9mFY 2025
Market capitalisationUSD 430mFY 2025 year end

About RxSight

RxSight develops and commercializes medical technology for customized vision following cataract surgery. Its RxSight Light Adjustable Lens system includes an adjustable intraocular lens, a light delivery device, and related accessories. After lens implantation, eye doctors use the device to adjust the lens based on the patient’s refractive needs, allowing post-surgical changes to the visual correction. The system is used in premium cataract procedures.

Generate the RxSight report

RxSight is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for RxSight and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on RxSight

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.